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RASAL1Progression of chronic kidney disease remains a principal problem in clinical nephrology and there is a pressing
need for novel therapeutics and biomarkers. Aberrant promoter CpG island methylation and subsequent tran-
scriptional silencing of speciﬁc genes have emerged as contributors to progression of chronic kidney disease.
Here, we report that transcriptional silencing of the Ras-GTP suppressor RASAL1 contributes causally to progres-
sion of kidney ﬁbrosis and we identiﬁed that circulating methylated RASAL1 promoter DNA fragments in periph-
eral blood correspond with levels of intrarenal levels of RASAL1 promoter methylation and degree of ﬁbrosis in
kidney biopsies, enabling non-invasive longitudinal analysis of intrarenal CpG island methylation.
Retrospective analysis of patientswith hypertensivenephrosclerosis revealed that circulatingmethylatedRASAL1
promoter DNA fragments in peripheral blood decrease with Dihydralazine treatment in patients with hyperten-
sive nephrosclerosis, and provided evidence that low-dose Dihydralazine delays decline of excretory kidney
function, whereas Dihydralazine at standard doses had no protective effect. We demonstrate that the protective
effect of Dihydralazine is due to induction of endogenous Tet3/Tdg-mediated DNA-de-methylation activity re-
versing aberrant promoter CpG island methylation, while HIF1α induction at standard doses counterbalances
its protective activity. We conclude that RASAL1 promoter methylation is a therapeutic target and a biomarker
of renal ﬁbrosis. Our study suggests that therapeutic use of low-dose Dihydralazine in patients with chronic kid-
ney disease and ﬁbrosis deserves further consideration.
© 2014 Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).and Rheumatology, Göttingen
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Progression of chronic kidney disease (CKD) remains an unsolved
problem in nephrology as effective drugs to slow down or even reverse
CKD progression are not yet available for clinical use (Science
JMECfCDaC, 2012). Because the common pathological alteration in vir-
tually every progressive CKD is renal ﬁbrosis, several anti-ﬁbrotic agents
are among leading candidates for CKD and have ﬁnally entered clinical
testing (Tampe and Zeisberg, 2014a). However, it may still take years
until new treatment regimens are approved and established for clinical
practice. Current management of CKD mainly aims at treating underly-
ing conditions and cardiovascular risk factors (Science JMECfCDaC,
2012). As CKD is commonly associated with hypertension, most preva-
lent pharmacological interventions include angiotensin-converting en-
zyme inhibitors (ACEIs), angiotensin-II receptor blockers (ARBs), beta
blockers, diuretics, statins and calcium channel blockers (Science
JMECfCDaC, 2012; Rayner et al., 2014). Of these, only ACEIs and ARBsense (http://creativecommons.org/licenses/by/3.0/).
20 B. Tampe et al. / EBioMedicine 2 (2015) 19–36have demonstrated the ability to slow progression of CKD, albeit only in
patients with marked proteinuria, these classes of drugs are currently
considered ﬁrst-line treatments (James et al., 2014). Due to the immi-
nent clinical need for effective anti-ﬁbrotic therapies, identiﬁcation of
additional, already approved drugs with reno-protective potential
would be highly desirable.
In this regard, aberrantmethylation of genomic DNA has emerged as
a novel therapeutic target. DNAmethylation in general refers tomethyl-
ation of cytosine bases that are clustered in so-called CpG-islands.Meth-
ylation of CpG islands within promoter regions effectively silences
expression of affected genes. While methylation of promoter CpG
islands is a physiological mechanism to determine cell lineage and dif-
ferentiation, aberrant promoter methylation (typically referred to as
hypermethylation) and subsequent transcriptional silencing of affected
genes are potent contributors to carcinogenesis. Recent studies demon-
strated that aberrant promoter CpG island methylation also plays a role
in renal ﬁbrosis (and in ﬁbrosis involving other organs aswell) (Bechtel
et al., 2010; Tampe et al., 2014). The importance of aberrant promoter
CpG island methylation is highlighted by the effectiveness of 5′-
Azacytidine, the ﬁrst de-methylating agent which was approved for
clinical use for patients with high-risk myelodysplastic syndrome
(MDS) and acute myeloid leukemia (Zeisberg and Zeisberg, 2013).
With regard to chronic kidney disease, administration of 5′-Azacytidine
ameliorated ﬁbrosis in several models of experimental chronic kidney
injury (Bechtel et al., 2010). 5′-Azacytidine is a broad de-methylating
agent which – as a cytidine analog – inhibits DNA methyltransferase 1
(DNMT1) and is incorporated into the DNA of dividing cells prompting
DNA repair and replacement of methylated CpGs with naked cytosine
(Foulks et al., 2012; Tampe and Zeisberg, 2014b; Tampe and Zeisberg,
2012). Due to DNA-incorporation, 5′-Azacytidine and its derivate 5′-
Aza-2′-Deoxycytidine have considerable cytotoxicity in addition to
their unspeciﬁc de-methylating activity. Hence, more speciﬁc normali-
zation of aberrant hypermethylation without incorporation of poten-
tially toxic nucleotide analogs would be much more attractive.
In this regard, Hydralazine (syn. 1-Hydrazinylphthalazine) was pri-
marily synthesized by Ciba as an anti-hypertensive compound and has
long been known to possess de-methylating activity (Arce et al., 2006;
Druey, 1949). In clinical studies, Hydralazine and its derivate
Dihydralazine were effective in de-methylating and re-activating ex-
pression of aberrantly silenced genes in cancer patients and a recent
phase III clinical study demonstrated delayed cancer progression in pa-
tients receiving Hydralazine (Coronel et al., 2011). After its introduction
to the clinic in 1952 as an anti-hypertensive drug, Hydralazine became
part of the standard triple-regimen (Hydrochlorothiazide, Propranolol
and Hydralazine) (Heagerty et al., 1982). With the emergence of ACEIs
and ARBs as anti-hypertensive drugs with cardio-protective activity,
Hydralazine today is mainly used as a third-line drug in patients with
therapy-resistant hypertension (Leonetti et al., 1990). Due to it being
highly safe, it is still a ﬁrst-line therapy for hypertension during preg-
nancy (James et al., 2014). To our knowledge, its effectiveness to de-
crease the prevalence of ESRD has not yet been assessed. The aim of
this study was to elucidate the potential of Hydralazine to correct aber-
rant DNAmethylation in ﬁbrotic kidneys and subsequently inhibit renal
ﬁbrogenesis.
2. Materials and Methods
2.1. Unilateral Ureteral Obstruction (UUO)
Eight to twelve week old CD57BL/6 mice were anesthetized with
isoﬂurane inhalation, analgesia was performed by subcutaneous
Buprenorphine injection. The ureter was separated from the surrounding
tissues and two ligatureswere placed about 5mmapart in the upper two-
thirds of the ureter of the left kidney to obtain reliable obstruction. On the
same day after surgery and recovery, mice were treated with either vehi-
cle buffer PBS, 5′-Azacytidine (10 mg/kg/day, Sigma, St. Louis, USA), low-dose, or high-dose Hydralazine (5 mg/kg/day or 50 mg/kg/day, respec-
tively, Sigma, St. Louis, USA) given intraperitoneally every other day.
Mice were sacriﬁced at indicated time points after ureter ligation
(Tampe et al., 2014).
2.2. Folic Acid-induced Nephropathy (FA)
Kidney injury was induced with a single intraperitoneal injection of
folic acid (250 mg/kg body weight in PBS) in CD1mice. Injections with
vehicle buffer PBS, 5′-Azacytidine (10 mg/kg/day, Sigma, St. Louis,
USA), and Hydralazine (5 mg/kg/day or 50 mg/kg/day, respectively,
Sigma, St. Louis, USA) were done intraperitoneally every other day on
day three after induction of folic acid until day 28. Mice were sacriﬁced
96 and 147 days after induction.
2.3. rtTAhCMV;hRASAL1-pTreTight Transgenic Mice
From three days before unilateral ureteral obstruction (UUO) on,
wildtype and rtTAhCMV;hRASAL1-pTreTight transgenic mice received ei-
ther vehicle buffer or doxycycline (DOX, 2 mg/ml, Clontech, Mountain
View, USA) within drinking water and renewed every two days. Mice
were sacriﬁced at indicated time points after ureteral ligation.
2.4. Histology
Parafﬁn-embedded kidneys were sectioned at 3 μm and Masson's
Trichrome Stain (MTS) was performed at the BIDMC Histopathology
Core and the University Medical Center Göttingen. We assessed the ﬁ-
brotic area using cellSens (Olympus, Tokyo, Japan) software, as previ-
ously described (Tampe et al., 2014; Sugimoto et al., 2012).
2.5. Immunoﬂuorescence
For immunoﬂuorescent staining, primary antibodies against α-
smooth muscle actin (αSMA, Abcam, Cambridge, UK) and ﬁbroblast-
speciﬁc protein 1 (Fsp1, Sigma, St. Louis, USA), and Alexa Fluor 568
(Invitrogen, Carlsbad, USA) secondary antibodies were used. Nuclear
staining was performed using 4′,6-diamidino-2-phenylindole (DAPI,
Vector Labs, Burlingame, USA). Relative areas positive for αSMA and
Fsp1 per visual ﬁelds were analyzed at original magniﬁcation ×40, rep-
resentative confocal pictures are shown at original magniﬁcation ×63.
2.6. Serum Creatinine Measurement
Creatinine concentrationwasmeasured using the colorimetric assay
Quantichrome DICT-500 (BioAssays, Hayward, USA) according the
manufacturer's directions, as previously described (Sugimoto et al.,
2012; LeBleu et al., 2009).
2.7. Cell Culture
Primary murine kidney ﬁbroblasts were isolated as described in our
previous publications with minor modiﬁcations (Bechtel et al., 2010;
Tampe et al., 2014). Kidneys were harvested and cultured in DMEM
(Gibco, Carlsbad, USA) supplemented with 2 mmol/l L-glutamine,
100 g/ml penicillin, 100 g/ml streptomycin and 20% heat-inactivated
fetal bovine serum (FBS, Cellgro, Manassas, USA) at 37 °C in 5% CO2. Pri-
mary kidney ﬁbroblasts emerged within few days as adherent cells on
the monolayer and were maintained in DMEM (Gibco, Carlsbad, USA)
supplemented with 2 mmol/l L-glutamine, 100 g/ml penicillin, 100 g/ml
streptomycin and 10% heat-inactivated fetal bovine serum (FBS, Cellgro,
Manassas, USA) at 37 °C in 5% CO2. Fibroblasts of passages 2 to 4 were
used. For RNA and DNA extraction, primary murine kidney ﬁbroblasts
were incubated with serum-free media containing 5′-Azacytidine (100
or 150 μg/ml in PBS, Sigma, St. Louis, USA), Hydralazine (10 or 50 μg/ml
in PBS, Sigma, St. Louis, USA) or doxycycline (DOX, 1 μg/ml, Clontech,
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Fig. 1.Hydralazine administration ameliorates experimental kidney ﬁbrosis and ﬁbroblast accumulation in the mouse model of unilateral ureteral obstruction (UUO). (A) Representative pho-
tomicrographs ofMasson's trichrome-stained (MTS) kidneys or sections immunolabeledwith primary antibodies againstα-smoothmuscle actin (αSMA)orﬁbroblast-speciﬁc protein 1 (Fsp1).
Thepanels showﬁbrotic kidney sections frommice challengedwithUUOat indicated timepoints after ureteral obstruction. As compared to controlmice receiving vehicle buffer, treatmentwith
de-methylating 5′-Azacytidine or Hydralazine attenuated renal ﬁbrogenesis and ﬁbroblast accumulation (scale bars: 50 μm). (B–D) The time course summarizes average mean values at the
indicated timepoints of each group (n=6 in each group, data are presented asmeans± s.e.m. *p b 0.05, values of pwere calculated respective to vehicle-treatedUUOmice). (E)Weperformed
methylated DNA immunoprecipitation (MeDIP) to assess the effect of anti-ﬁbrotic 5′-Azacytidine and Hydralazine treatment (10 mg/kg/day or 5 mg/kg/day respectively) on Rasal1 promoter
methylation inmouse kidneys that were challenged with unilateral ureteral obstruction (UUO). In this assay, fragmented total kidney DNA (input DNA) was exposed to antibodies that specif-
ically capture methylated DNA (5mC DNA). The captured DNA is eluted and analyzed by primers speciﬁc to Rasal1 promoter, electrophoresis of PCR products was performed on a Bioanalyzer.
Thepictures display virtual gel images ofRasal1PCRproducts of captured (methylated, 5mC)DNA, the bottompictures displayRasal1PCRproducts of inputDNA(as controls for equal loading in
immunoprecipitation). Rasal1was hypermethylatedwhen kidneys had developed severe tubulointerstitial ﬁbrosis ten days after ureteral obstruction (UUO+ vehicle), whereas Rasal1 hyper-
methylationwas ameliorated inmice treatedwith de-methylating 5′-Azacytidine (UUO+ 5′-Azacytidine) or Hydralazine (UUO+ Hydralazine). (F) Rasal1mRNA expressionwas analyzed by
qRT-PCR in RNA isolated from total kidneys. For statistical analysis, UUOmice treated with vehicle buffer PBS, with de-methylating 5′-Azacytidine, or Hydralazine were compared to sham-op-
erated controls arbitrarily set to one. Rasal1 expressionwas suppressed in kidneys ofmicewhich had been challengedwith UUO andwhich had received vehicle buffer PBS, butwas restored in
kidneys ofmice treatedwith 5′-Azacytidine orHydralazine (n=4 in each group, experimentswere done in triplicate, data are presented asmeans± s.e.m. *pb 0.05, values of pwere calculated
respective to vehicle-treated UUOmice).
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Fig. 2. Effect of transgenic RASAL1 over-expression on experimentalﬁbrogenesis andﬁbroblast accumulation. (A) Representative photomicrographs ofMasson's trichrome-stained (MTS),
αSMA or Fsp1 immunolabeled kidney sections from wildtype and rtTAhCMV;hRASAL1-pTreTightmice receiving vehicle buffer PBS (−DOX) or doxycycline (+DOX). The panels show ﬁ-
brotic kidney sections from mice challenged with ureteral obstruction (UUO) three, seven and ten days after obstruction. As compared to control mice receiving vehicle buffer PBS
(rtTAhCMV;hRASAL1-pTreTight− DOX), enhanced RASAL1 expression in induced transgenic mice (rtTAhCMV;hRASAL1-pTreTight+ DOX) is associated with ameliorated ﬁbrogenesis in
the kidney (scale bars: 50 μm). (B–D) The time course summarizes average mean values at the indicated time points of each group (n = 5 in each group, data are presented as
means± s.e.m. *p b 0.05, values of pwere calculated respective to vehicle-treated rtTAhCMV;hRASAL1-pTreTight transgenic mice). (E) Primary ﬁbroblasts were seeded into six-well plates
at a density of 60,000 cells per well, trypsinized, and counted after 24 and 48 h. As compared to wildtype (wildtype-DOX, wildtype+ DOX) or transgenic ﬁbroblast cultures treated with
vehicle buffer PBS (rtTAhCMV;hRASAL1-pTreTight− DOX), enhanced RASAL1 expression in induced transgenic ﬁbroblasts (rtTAhCMV;hRASAL1-pTreTight+ DOX) normalized increased
proliferative activity of ﬁbrotic ﬁbroblasts (experiments were replicated four times, data are presented as means± s.e.m. *p b 0.05, values of pwere calculated respective to two days ve-
hicle-treated rtTAhCMV;hRASAL1-pTreTight ﬁbroblasts).
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23B. Tampe et al. / EBioMedicine 2 (2015) 19–36Mountain View, USA). Cells were harvested for further analysis one and
two days after incubation.
2.8. In Vitro Transfection
Cells were seeded in culture ﬂasks in antibiotic-free DMEM (Gibco,
Carlsbad, USA) supplemented with 10% heat-inactivated fetal bovine
serum (FBS, Cellgro, Manassas, USA). For knockdown experiments,
600 pmol siRNA or scrambled siRNA (Santa Cruz Biotechnology, Santa
Cruz, USA) was transfected using Lipofectamine 2000 reagent
(Invitrogen, Carlsbad, USA). After 12 h of incubation, transfection medi-
um was replaced, cells were seeded in six-well culture plates at a con-
centration of 60,000 per well and incubated with serum-free media
containing 5′-Azacytidine (100 or 150 μg/ml in PBS, Sigma, St. Louis,
USA) or Hydralazine (10 or 50 μg/ml in PBS, Sigma, St. Louis, USA).
Cells were harvested for further analysis after 24 and 48 h of incubation.
2.9. RNA Isolation
Cells were dissolved in TRIzol (Invitrogen, Carlsbad, USA), tissuewas
shredded using TissueLyser LT (Qiagen, Hilden, Germany). RNAwas iso-
lated using PureLink RNAMini Kit (Ambion, Carlsbad, USA) according to
the manufacturer's protocol.
2.10. Quantitative Real-time PCR Quantiﬁcation (qRT-PCR)
For SYBR-based real-time PCR, cDNA synthesis was performed by
using DNase I digestion and SuperScript II Reverse Transcriptase
(Invitrogen, Carlsbad, USA) according to the manufacturer's protocol.
1 μl of reverse-transcribed cDNAwas added to the reactionmixture con-
taining the primer pair (200 nmol/l each) and diluted 2× Fast SYBR
GreenMasterMix (Applied Biosystems, Carlsbad, USA) in a ﬁnal volume
of 20 μl for each PCR reaction. The real-time PCR reactions were per-
formed in a 96-well reaction plate using the StepOne Real-Time System
(Applied Biosystems, Carlsbad, USA) and were done in triplicates. An
initiation step at 95 °C for 20 s was followed by 40 cycles at 95 °C for
3 s and 60 °C for 30 s, with 1 cycle of dissociation at 95 °C for 15 s,
60 °C for 60 s, and 95 °C for 15 s. The intercalation of SYBR Green dye
and its ﬂuorescent signal is directly proportional to the amount of am-
pliﬁed DNA and was transformed into the cycle threshold (Ct). For nor-
malization, the Ct values of the housekeeping gene were subtracted
from the Ct values of the gene of interest to generate the dCt values.
The relative expression levels were calculated using the equation
2−ddCt. Oligonucleotide sequences are shown in Supplementary Table A.
2.11. DNA Isolation
Tissue and cells were dissolved in TRIzol (Invitrogen, Carlsbad, USA),
tissue was shredded using TissueLyser LT (Qiagen, Hilden, Germany).
DNA from tissue, cells and peripheral blood samples was isolated
using DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany) according
to the manufacturer's protocol.
2.12. Isolation of Methylated, Hydroxymethylated, Carboxylated DNA
Methylated DNA was isolated from 1.0 μg of sonicated DNA
using Methylamp Methylated DNA Capture (MeDIP) Kit,
hydroxymethylated DNA was isolated from 0.5 μg of sonicated DNA
using EpiQuik Hydroxymethylated DNA Immunoprecipitation
(hMeDIP) Kit (Epigentek, Farmingdale, USA). Carboxylated DNA
was isolated using 1.0 μg of sonicated DNA for immunoprecipitation
with 5-carboxyl-cytosine antibody (Active Motif, Carlsbad, USA).
DNA was added to each antibody coated well and incubated for
120 min at room temperature on an orbital shaker. After releasing
with proteinase K for 60 min at 65 °C, DNA was eluted from the col-
umn and adjusted to a ﬁnal volume of 100 μl with nuclease-freewater. For each sample, an input vial was performed using total son-
icated DNA for further normalization.
2.13. SYBR-based Ampliﬁcation of Methylated, Hydroxymethylated,
Carboxylated Rasal1/RASAL1
For DNA ampliﬁcation, 5 μl of eluted DNA was added to the reaction
mixture containing the primer pair (300 nmol/l each), a ROX passive
reference dye (Bio-Rad, Hercules, USA) and diluted 2× SYBR green
Supermix (Bio-Rad, Hercules, USA) in a ﬁnal volume of 25 μl for each
PCR reaction. The real-time PCR reactions were performed in a 96-
well reaction plate using the Mx3000P QPCR System (Stratagene,
Santa Clara, USA). PCR reactionwas stoppedwhen theﬂuorescent signal
increased over the threshold and electrophoresis of PCR products was
done on a Bioanalyzer 2100 (Agilent Technologies, Santa Clara, USA) ac-
cording to the manufacturer's protocol. Electrophoresis results are
shown as virtual gel images as described in our previous publications
(Bechtel et al., 2010; Tampe et al., 2014). For quantiﬁcation of intrarenal
and circulating methylated Rasal1/RASAL1 promoter DNA fragments,
the Ct values of the input samples were subtracted from the Ct values
of the MeDIP samples after enrichment to generate the dCt values
used in the equation 2−dCt. Oligonucleotide sequences are shown in
Supplementary Table B.
2.14. Methylation-speciﬁc PCR
Bisulﬁte conversion was performed using Cells-To-CpG Bisulﬁte
Conversion Kit (Applied Biosystems, Carlsbad, USA) according to the
manufacturer's protocol. Brieﬂy, 2 μg genomic DNA was denaturated
for 10 min at 50 °C, conversion of unmethylated cytosines to uracil
was performed in 2 cycles at 65 °C for 30 min, followed by 95 °C for
90 s using a thermal cycler (Eppendorf, Hamburg, Germany).
Methylation-speciﬁc PCR was performed using primers speciﬁcally
targeting converted (unmethylated) or unconverted (methylated)
CpG sites. Oligonucleotide sequences are shown in Supplementary
Table C.
2.15. Western Blot Analyses
Tissue and cells were homogenized in NP40 lysis buffer (Invitrogen,
Carlsbad, USA) supplemented with protease cocktail inhibitor (Roche,
Basel, Switzerland). After sonication, proteins were resolved by Tris-
acetate-SDS acrylamide gel electrophoresis and transferred onto PVDF
membranes (Invitrogen, Carlsbad, USA) and blocked in 5% dry milk in
TBS-T (TBS pH 7.6, 0.1% Tween-20). After incubation with respective
primary antibodies against Dnmt1 (B-Bridge, Cupertino, USA), Tet3
(Genetex, San Antonio, USA), Tdg (Santa Cruz Biotechnology, Santa
Cruz, USA), HIF1α (Invitrogen, Carlsbad, USA), β-actin (Sigma, St.
Louis, USA) and Gapdh (HyTest, Turku, Finland), secondary HRP-
conjugated antibodies were used (Dako, Glostrup, Denmark). Lumines-
cence was detected on a ChemiDoc XRS system (Bio-Rad, Hercules,
USA) using chemiluminescent substrate (Cell Signaling, Danvers, USA).
2.16. Kidney Biopsies and Human Peripheral Blood Samples
Detailed clinical patient data are presented in Supplementary
Tables D–G.
2.17. Statistical Analysis
ANOVAwas used for multiple comparisons of mouse samples to de-
termine signiﬁcance. Student's t-test analysis was used for the single-
parameter comparisons. Statistical signiﬁcance was deﬁned as values
of *p b 0.05. Prism 5 software (GraphPad, La Jolla, USA)was used for sta-
tistical analysis.
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All experimental animal studies have been carried out with the ap-
proval of the Institutional Animal Care and Use Committee of the Beth
Israel Deaconess Medical Center or the University Medical Center
Göttingen. The use of parts of kidney biopsies and peripheral blood sam-
ples for research purposeswas approved by the Ethics Committee of the
UniversityMedical Center Göttingen, andwritten consentwas obtained
from all subjects before kidney biopsy.
3. Results
3.1. Hydralazine Ameliorates Experimental Renal Fibrosis in Mice
Based on encouraging studies demonstrating the de-methylating ac-
tivity of Hydralazinewith regard to cancer cells, we ﬁrst aimed to deter-
mine if this de-methylating activity could be utilized to inhibit renal
ﬁbrogenesis, as was previously shown for the prototypical (yet more
toxic) de-methylating drug 5′-Azacytidine (Bechtel et al., 2010). For
this purpose, we opted to challenge C57BL/6micewithunilateral ureter-
al obstruction (UUO) and to administer Hydralazine intraperitoneally at
a dose of 5 mg/kg/day, which has been established as an optimum reg-
imen in murine cancer studies (Chavez-Blanco et al., 2006). We chose
theUUOmodel becauseﬁbrosis in the obstructed kidney developswith-
out hypertension, pre-empting possible misinterpretation due to possi-
ble anti-hypertensive activity of Hydralazine (Fern et al., 1999;Ma et al.,
2003; Manucha et al., 2004; Sugiyama et al., 2005). To directly compare
the effectiveness of Hydralazine to that of 5′-Azacytidine, we also in-
cluded a cohort of mice which received 5′-Azacytidine (10 mg/kg/day
intraperitoneally as established as an optimum dose in previous stud-
ies), and we sacriﬁced cohorts of mice at pre-determined time-points
for tissue analysis (Bechtel et al., 2010). After 10 days of ureteral ob-
struction, kidneys ofmice that had received either 5′-Azacytidine orHy-
dralazine displayed signiﬁcantly less ﬁbrosis, as compared to kidneys of
control UUO-challenged mice (which had received vehicle buffer PBS)
(Fig. 1A, B). Ameliorated ﬁbrosis correlated with blunted accumulation
of ﬁbroblasts (determined by quantiﬁcation of αSMA and Fsp1
immunolabeling) (Fig. 1A–D). To further validate this observation, we
aimed to challengemice of different genetic backgroundswith a disease
model of distinct pathomechanism. For this purpose, we challenged CD1
mice with a single injection of folic acid (FA, which results in severe
renal ﬁbrosis within 5 months) and administered 5′-Azacytidine or Hy-
dralazine at 10 mg/kg/day and 5 mg/kg/day, respectively, from day 3 to
day 21 after the folic acid injection. Rationale for using this approach
was that we previously established this treatment schedule to be effec-
tivewhen 5′-Azacytidinewas administered in this model (Bechtel et al.,
2010). After 5 months, kidneys developed severe tubulointerstitial ﬁ-
brosis, however, kidneys of mice which received 5′-Azacytidine or Hy-
dralazine displayed signiﬁcantly less ﬁbrosis as compared to kidneys
of control mice (which received vehicle buffer PBS) (Supplementary
Fig. 1A, B). Ameliorated ﬁbrosis in mice which received 5′-Azacytidine
or Hydralazine correlated with blunted rise of serum creatinine levels
(Supplementary Fig. 1C) and ameliorated ﬁbroblast accumulation (Sup-
plementary Fig. 2A–D). As compared toHydralazine-treatedmice, ﬁbro-
sis and plasma creatinine levels were lower in 5′-Azacytidine-treatedFig. 3. Treatment with de-methylating 5′-Azacytidine or Hydralazine restores Rasal1 m
hydroxymethylation and carboxylation. (A) Methylation status of the Rasal1 promoter in prim
de-methylating 5′-Azacytidine (100 μg/ml or 150 μg/ml) or Hydralazine (10 μg/ml or 50 μg/m
methylation observed in ﬁbrotic ﬁbroblasts. (B) Rasal1 mRNA expression levels were analyzed
inﬁbroticﬁbroblast cultureswere restored after treatmentwith de-methylating 5′-Azacytidine
*p b 0.05, values of pwere calculated respective to two days vehicle-treated ﬁbrotic ﬁbroblast cu
per well, trypsinized and counted after 24 and 48 h. Compared to non-ﬁbrotic ﬁbroblasts, ﬁbro
5′-Azacytidine or Hydralazine normalized ﬁbrotic ﬁbroblast proliferation (experiments were r
culated respective to two days vehicle-treated ﬁbrotic ﬁbroblast cultures). (D) DNA hydroxy
these modiﬁcations were detected in ﬁbrotic ﬁbroblasts upon treatment with 5′-Azacyt
hydroxymethylation and Rasal1 carboxylation indicating active enzymatic DNA de-methylatiomice, albeit differences between the groups did not reach statistical sig-
niﬁcance (Supplementary Figs. 1A–C and 2A–D).
3.2. Reno-Protective Effect of Hydralazine and Rasal1 Promoter CpG Island
De-methylation
We next aimed to elucidate if ameliorated ﬁbrosis observed upon
Hydralazine treatment was due to its de-methylating efﬁcacy. For this
purpose, we analyzed Rasal1 promoter CpG islandmethylation in geno-
mic DNA samples isolated from total kidney tissues. We focused on
Rasal1methylation because we previously identiﬁed RASAL1 (encoding
for RASAL1, synonymRas-GAP-like protein, and inhibitor of Ras-GTP) to
be selectivelymethylated in ﬁbrotic kidney biopsies utilizing a genome-
wide methylation screen and we veriﬁed that Rasal1 promoter CpG is-
land methylation correlated with degree of ﬁbrosis in murine models
of renal ﬁbrosis (including UUO and folic acid-induced nephropathy)
as well as in renal biopsies (Bechtel et al., 2010; Tampe et al., 2014). Fi-
brosis upon challenge with UUO was associated with increased Rasal1
CpG island promoter methylation (Fig. 1E), whereas ameliorated ﬁbro-
sis upon Hydralazine administration correlated with reduced Rasal1
methylation, similar to observations after administration of the proto-
typical de-methylating agent 5′-Azacytidine (Fig. 1E). A similar associa-
tion of ﬁbrosis, anti-ﬁbrotic efﬁcacy of 5′-Azacytidine or Hydralazine
administration and degree of Rasal1 CpG island promoter methylation
was documented when kidneys of folic acid-challengedmice were ana-
lyzed (Supplementary Fig. 3A). Normalization of Rasal1 CpG island pro-
moter methylation upon treatment with 5′-Azacytidine or Hydralazine
was associated with normalization of Rasal1mRNA expression in both
mouse models used (Fig. 1F and Supplementary Fig. 3B), suggesting
that the anti-ﬁbrotic efﬁcacy of both 5′-Azacytidine and Hydralazine is
facilitated through de-methylation and subsequent transcriptional re-
activated of aberrantly methylated genes, including Rasal1.
To further substantiate the link of aberrant Rasal1 promotermethyl-
ation, progressive renal ﬁbrosis and the reno-protective efﬁcacy of de-
methylating compounds 5′-Azacytidine and Hydralazine, we next chal-
lenged transgenic mice harboring transgenes for doxycycline-inducible
RASAL1 over-expression (rtTAhCMV;hRASAL1-pTreTight) with UUO
(Supplementary Fig. 4A, B). These mice display robust RASAL1 over-
expression upon administration of doxycycline and transgene expres-
sion is under control of CMV minimal promoter which is devoid of
CpG islands and hence resistant to potential transcriptional silencing
through promoter methylation when challenged with experimental
kidney ﬁbrosis (Supplementary Fig. 4C). When challenged with unilat-
eral ureteral obstruction (UUO), kidneys of wildtype and
rtTAhCMV;hRASAL1-pTreTight mice that did not receive doxycycline
(−DOX) developed severe ﬁbrosis within 10 days (Fig. 2A, B). Fibrosis
was signiﬁcantly ameliorated in rtTAhCMV;hRASAL1-pTreTightmice in
which RASAL1 over-expressionwas induced in response to doxycycline
administration (+DOX) (Fig. 2A, B). Ameliorated ﬁbrosis in
doxycycline-stimulated rtTAhCMV;hRASAL1-pTreTight mice (+DOX)
correlated with blunted accumulation of ﬁbroblasts, assessed through
immunolabeling using antibodies against αSMA and Fsp1 (Fig. 2A–D),
demonstrating that ﬁbroblast activation is attenuated and kidneys are
protected when transcriptional suppression of Rasal1 is abolished. In
primary ﬁbroblast cultures of rtTAhCMV;hRASAL1-pTreTight mice,RNA expression due to Rasal1 promoter de-methylation, involving Rasal1 promoter
ary mouse kidney ﬁbroblasts out of non-ﬁbrotic and ﬁbrotic tissues after treatment with
l) for 24 and 48 h was analyzed by MeDIP. Treatment normalized aberrant Rasal1 hyper-
by qRT-PCR at time points indicated. Decreased Rasal1 mRNA expression levels observed
or Hydralazine (experimentswere done in triplicate, data are presented asmeans± s.e.m.
ltures). (C) Primary ﬁbroblasts were seeded into six-well plates at a density of 60,000 cells
tic ﬁbroblasts are characterized by increased proliferative activity whereas treatment with
eplicated four times, data are presented as means ± s.e.m. *p b 0.05, values of pwere cal-
methylation and carboxylation were analyzed by hMeDIP and CaDIP. Whereas none of
idine, Rasal1 promoter de-methylation after Hydralazine treatment involves Rasal1
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27B. Tampe et al. / EBioMedicine 2 (2015) 19–36RASAL1 induction upon doxycycline administration normalized in-
creased intrinsic proliferative activity of ﬁbrotic ﬁbroblasts (Fig. 2E). In
summary, we established that Hydralazine is reno-protective in mice
when administered at established de-methylating doses, reno-
protective efﬁcacy of Hydralazine correlates with amelioration of
Rasal1 promoter methylation, prevention of Rasal1 transcriptional si-
lencing is causally reno-protective and the reno-protective efﬁcacy of
Hydralazine is similar to that of the prototypical de-methylating sub-
stance 5′-Azacytidine.
3.3. Hydralazine De-methylates Rasal1 in Fibrotic Renal Fibroblasts
To further substantiate the link between Hydralazine's reno-
protective efﬁcacy and its de-methylating activity, we next aimed to ex-
plore themechanismswhich underlie its effect on DNA de-methylation.
It is well established that the prototypical de-methylating drug 5′-
Azacytidine has a bimodal function, as it directly inhibits Dnmt1 (DNA
methyltransferase 1, the enzyme which facilitates DNA methylation)
and it is incorporated into DNA as cytosine analog prompting DNA re-
pair and replacement of methylated CpGs with naked cytosine (Foulks
et al., 2012). In contrast, the mechanisms which underlie de-
methylating activity of Hydralazine are still elusive. To gain insights
into the de-methylating activity of Hydralazine, we utilized an
established cell culture system involving primary renal ﬁbroblasts. We
previously described that ﬁbroblasts from ﬁbrotic kidneys (which dis-
play an activated phenotype associated with increased autonomous
proliferative activity) are characterized by aberrant promoter CpG-
island methylation of Rasal1 (Bechtel et al., 2010; Tampe et al., 2014).
We also demonstrated that 5′-Azacytidine effectively de-methylated
Rasal1 and that rescue of endogenous Rasal1 expression normalized
proliferative activity of ﬁbrotic renal ﬁbroblasts (to the level of non-
ﬁbrotic ﬁbroblasts) (Bechtel et al., 2010; Tampe et al., 2014). Here we
demonstrate that the addition of Hydralazine to cell culture media de-
methylated Rasal1 promoter CpG islands (Fig. 3A and Supplementary
Fig. 5A, B), associated with re-activation of Rasal1 expression (Fig. 3B).
De-methylating activity was less effective than 5′-Azacytidine, which
caused Rasal1 de-methylation at optimum dosage within 24 h
(Fig. 3A), similar to what has been observed in cancer cells (Chuang
et al., 2005). In control experiments, neither 5′-Azacytidine nor Hydral-
azine signiﬁcantly stimulated Rasal1 expression in non-ﬁbrotic ﬁbro-
blasts in which Rasal1 promoter CpG islands are not substantially
methylated (Supplementary Fig. 6A, B). Rasal1 re-expression upon 5′-
Azacytidine or Hydralazine exposure correlated with normalization of
increased proliferative activity of ﬁbrotic renal ﬁbroblasts (Fig. 3C),
whereas proliferation of non-ﬁbrotic ﬁbroblasts was not affected by ei-
ther 5′-Azacytidine or Hydralazine (Supplementary Fig. 6C), establish-
ing that Hydralazine effectively restores Rasal1 expression by inducing
de-methylation of its CpG island promoter, resulting in normalization
of intrinsic proliferative activity.
We next aimed to gain insights into themechanismswhich underlie
Hydralazine-mediated Rasal1 promoter de-methylation. Because Hy-
dralazine is not incorporated into DNA, we hypothesized that Hydral-
azine acts by inducing endogenous de-methylating mechanisms. In
general, methylated DNA can be de-methylated either through passive
or active mechanisms. Passive de-methylation can occur whenFig. 4. Hydralazine-induced de-methylation of Rasal1 promoter is mediated through active
(A) Analyzed by qRT-PCR, mRNA expression levels of DNA methyltransferases Dnmt1 and Dnm
were done in triplicate, data are presented as means± s.e.m. *p b 0.05, n.s. no signiﬁcance, valu
show virtual gel images of Rasal1 PCR products of immunoprecipitated DNA, the bottom pictu
CaDIP. Panels display representative analysis of cells which had been transfected with scramble
of Dnmts did not mediate rapid Rasal1 de-methylation as observed upon treatment with Hydra
anismsof active DNAde-methylation. (C) Fibroticﬁbroblast cultureswere subjected to vehicle b
PCR at indicated time points. Decreased Rasal1 mRNA expression levels observed in ﬁbrotic ﬁb
dralazine. Knockdown of Dnmts did not affect Rasal1 mRNA expression levels (experiments we
culated respective to two days vehicle-treated ﬁbrotic ﬁbroblast cultures). (D) Depletion of Dnm
Hydralazine were still capable to normalize intrinsic proliferative activity (experiments were r
culated respective to two days vehicle-treated cultures).methylation marks are not copied on the newly synthesized strands
meaning that during aﬁrst cell division, hemi-methylatedDNA is gener-
ated and themethylationmark is entirely removed upon the second cell
division (Bhutani et al., 2011). For rapid de-methylation to occur, active
de-methylation mechanisms involve oxidation of methylated cytosine
(5mC) to generate 5-hydroxymethyl-cytosine (5hmC), 5-formyl-
cytosine (5fC), and 5-carboxyl-cytosine (5caC) with subsequent base
excision and replacement with naked cytosine are required (Bhutani
et al., 2011).We observed that Rasal1 de-methylation uponHydralazine
exposure corresponded with increased Rasal1 hydroxymethylation and
Rasal1 carboxylation (but not upon exposure to 5′-Azacytidine)
(Fig. 3D), suggesting that Hydralazine mediates Rasal1 de-methylation
by active DNA de-methylation involving formation of Rasal1
hydroxymethylation and Rasal1 carboxylation. In control experiments,
neither 5′-Azacytidine nor Hydralazine signiﬁcantly stimulated Rasal1
hydroxymethylation and Rasal1 carboxylation in non-ﬁbrotic ﬁbro-
blasts (in which Rasal1 promoter CpG islands are not substantially
methylated) (Supplementary Fig. 6D).
3.4. Hydralazine-induced De-methylation Involves Tet3-mediated
Hydroxymethylation
To gain insights into the de-methylating activity of Hydralazine,
we ﬁrst analyzed expression levels of DNA methyltransferases
(Dnmts) which facilitate CpG islandmethylation. Hydralazine signif-
icantly reduced Dnmt1 mRNA and protein expression levels (Fig. 4A
and Supplementary Fig. 7A), whereas Dnmt3a and Dnmt3b were in-
creased upon Hydralazine exposure (Fig. 4A). However, knockdown
of Dnmts did not mediate Rasal1 de-methylation as observed upon
treatment with Hydralazine (Fig. 4B and Supplementary Fig. 8A).
When Dnmts were depleted, Hydralazine was still capable of induc-
ing Rasal1 hydroxymethylation and carboxylation (Fig. 4B), which
was associated with restoration of Rasal1 expression levels
(Fig. 4C), and normalization of increased proliferative activity of ﬁ-
brotic ﬁbroblasts (Fig. 4D), suggesting that Hydralazine-induced
de-methylation is mediated through active mechanisms in renal ﬁ-
broblasts and is not exclusively dependent on Dnmt1 inhibition.
Because Rasal1 de-methylation upon Hydralazine exposure
corresponded with increased Rasal1 hydroxymethylation (Fig. 3D), we
hypothesized that Hydralazine involved oxidation of methylated cyto-
sine through Tet proteins (Ten-Eleven Translocation enzymes) to gen-
erate hydroxymethylated cytosine, we next analyzed the effect of
Hydralazine on expression levels of Tet1, Tet2, and Tet3 (Tahiliani
et al., 2009; Ito et al., 2010). Of the three known Tets, we observed
that only Tet3 expression was induced upon Hydralazine exposure
(Fig. 5A and Supplementary Fig. 7B), siRNA-mediated depletion of
Tet3 prevented Hydralazine-induced Rasal1 de-methylation (Fig. 5B
and Supplementary Fig. 8B), restoration of mRNA expression levels
(Fig. 5C), and normalization of ﬁbrotic ﬁbroblast proliferation (Fig. 5D)
in response to Hydralazine, while Tet1 or Tet2 knockdown had no ef-
fects (Fig. 5B–D and Supplementary Fig. 8B). Neither Dnmt nor Tet de-
pletion affected Rasal1 de-methylation or transcriptional restoration
upon exposure to 5′-Azacytidine (Figs. 4B, C and 5B, C).
Because our data suggested that Hydralazine causes Rasal1 de-
methylation through a mechanism involving Tet3-mediatedmechanisms in renal ﬁbroblasts and not exclusively dependent on Dnmt1 inhibition.
t3a were normalized after treatment with 5′-Azacytidine and Hydralazine (experiments
es of pwere calculated respective to vehicle-treated ﬁbrotic cultures). (B) The top pictures
res show PCR products of input DNA as controls for equal loading in MeDIP, hMeDIP, and
d siRNA (left) or with siRNAs targeting (from left to right) Dnmt1, -3a, or 3b. Knockdown
lazine suggesting that Rasal1 de-methylation upon Hydralazine exposure involves mech-
uffer, 5′-AzacytidineorHydralazine, Rasal1mRNAexpression levelswere analyzedbyqRT-
roblast cultures were restored after treatment with de-methylating 5′-Azacytidine or Hy-
re done in triplicate, data are presented as means ± s.e.m. *p b 0.05, values of pwere cal-
t1, -3a, or -3b did not affect proliferative activity of ﬁbrotic ﬁbroblasts, 5′-Azacytidine and
eplicated four times, data are presented as means ± s.e.m. *p b 0.05, values of p were cal-
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29B. Tampe et al. / EBioMedicine 2 (2015) 19–36hydroxymethylation, we next elucidated the involvement of
additional factors which are involved in replacement of
hydroxymethylated cytosines with naked cytosine bases. In
germline cells, hydroxymethylated cytosine is further oxidized to
5-formyl-cytosine (5fC) and 5-carboxyl-cytosine (5caC) before exci-
sion of 5caC by DNA glycosylase Tdg or Smug1, and restoration of cy-
tosine via follow-on base excision repair (Bhutani et al., 2011).
Alternatively, 5hmC is deaminated by the Aid/Apobec family of cyti-
dine deaminases, before Tdg-mediated base excision repair (Bhutani
et al., 2011). While upon exposure to Hydralazine, neither expres-
sion of deaminases Aicda, Apobec1, or Apobec3was signiﬁcantly reg-
ulated (Supplementary Fig. 7C), Tdg and Smug1 expression (which
facilitate base excision repair) were signiﬁcantly increased upon Hy-
dralazine treatment (Fig. 6A and Supplementary Fig. 7D). Only
siRNA-mediated depletion of Tdg effectively prevented Rasal1 de-
methylation (Fig. 6B and Supplementary Fig. 8C), mRNA restoration
(Fig. 6C), and normalization of ﬁbrotic ﬁbroblast proliferation
(Fig. 6D), suggesting that Hydralazine involves Tdg-mediated base
excision repair in facilitating Rasal1 de-methylation. In summary,
Hydralazine re-activated expression of Rasal1 in ﬁbrotic renal ﬁbro-
blasts through a mechanism involving Tet3-mediated Rasal1
hydroxymethylation, Tdg-mediated excision, and subsequent re-
placement with naked cytosine. Albeit the de-methylating activity
of Hydralazine was inferior to that of 5′-Azacytidine, it was sufﬁcient
enough to re-activate Rasal1 expression and normalize intrinsic pro-
liferative activity of ﬁbrotic renal ﬁbroblasts.3.5. Evidence for Tet3-mediated Rasal1 De-methylation in Hydralazine-
treated Mice
We next explored if the identiﬁed pathway was similarly involved
when kidneyswere protected from experimental ﬁbrogenesis uponHy-
dralazine administration.We analyzed expression of Dnmts, Tets, Aicda,
Apobecs, Tdg, and Smug1 by qRT-PCR in kidney lysates of mice which
had been challenged with ureteral obstruction (Fig. 7A–D, compare to
Fig. 1) or folic acid (Supplementary Fig. 9A–D, compare to Supplemen-
tary Fig. 1). In kidneys of mice that were challenged with UUO, blunted
ﬁbrosis upon either 5′-Azacytidine orHydralazine administration corre-
lated with suppressed Dnmt1 expression (Fig. 7A). Among Tet hydrox-
ylases, Hydralazine induced expression of Tet3, but not of Tet1 or Tet2,
whereas 5′-Azacytidine did not increase expression of either Tet gene
(Fig. 7B). Similar to results observed in cell culture, administration of
Hydralazine had no effect on expression levels of cytosine deaminases
Aicda, Apobec1, or Apobec3 (Fig. 7C), whereas DNA glycosylases Tdg
and Smug1 were induced after Hydralazine administration in UUO
mice (Fig. 7D). Induction of the Tet3/Tdg cascade correlated with in-
creased Rasal1 hydroxymethylation and Rasal1 carboxylation (Fig. 8A),
suggesting that mechanisms which mediate Rasal1 de-methylation in
Hydralazine-treated mice correspond to Hydralazine-induced de-
methylation in cultured renal ﬁbroblasts. Evidence for Tet3/Tdg-
mediated de-methylation of Rasal1 was similarly observed in folic acid
(FA)-challenged CD1 mice (Supplementary Figs. 9A–D and 10A). In
summary, our studies suggest that Hydralazine ameliorates experimen-
tal renal ﬁbrosis through inducing de-methylation of aberrantlyFig. 5.Normalization of Rasal1 promotermethylation upon de-methylating Hydralazine involve
with induction of DNA hydroxylase Tet3 in primary ﬁbrotic ﬁbroblast cultures (experiments w
values of p were calculated respective to vehicle-treated ﬁbrotic cultures). (B) Panels display r
with siRNAs targeting (from left to right) Tet1, -2, or -3. Whereas neither knockdown of Tet1
Rasal1 hydroxymethylation, or Rasal1 carboxylation, depletion of Tet3 resulted in failure of Hy
and Rasal1 carboxylation formation. (C) Fibrotic ﬁbroblast cultures were subjected to vehicle bu
qRT-PCR at indicated time points. Depletion of Tet1 and Tet2 did not affect the capacity of Hydr
decreased Rasal1 expression levels observed in ﬁbrotic ﬁbroblasts when Tet3 was depleted (ex
signiﬁcance, values of pwere calculated respective to vehicle-treated ﬁbrotic cultures). (D) Con
expression after Tet3 depletion, Hydralazine no longer decreased the proliferative activity of ﬁ
means ± s.e.m. *p b 0.05, n.s. no signiﬁcance, values of p were calculated respective to two daymethylated Rasal1 (and additional genes as well) by Dnmt1 inhibition
and by inducing the endogenous Tet3/Tdg de-methylation pathway.
3.6. CirculatingMethylated RASAL1 CpG Island Promoter Fragments Are Re-
duced in Patients on Dihydralazine Medication
Ourﬁndings that Rasal1 promoter CpG islandmethylation contribut-
ed to progression of renal ﬁbrosis, Hydralazine ameliorated aberrant
promoter methylation, and blunted renal ﬁbrosis and intrarenal Rasal1
promoter methylation levels correlate with Hydralazine therapy in
mice offered the attractive combination of a clinically approved drug
(Hydralazine and its derivate Dihydralazine) and a potential biomarker
in human patients (RASAL1 promoter methylation). However, the need
for a renal biopsy to assess intrarenal degree of RASAL1methylation ap-
peared prohibitive in this regard. Based on several studies which dem-
onstrated that aberrant CpG island promoter methylation within
tumors is reﬂected by circulating methylated promoter fragments, we
hypothesized that aberrant CpG island promoter methylation associat-
edwith renal ﬁbrosis could be similarly correlatedwith increased levels
of circulating DNA fragments (Schwarzenbach et al., 2011). Analysis of
circulating Rasal1 promoter DNA fragments in peripheral blood from
mice which had been challenged with either ureteral obstruction
(UUO) or folic acid (FA) and had received vehicle buffer PBS, 5′-
Azacytidine, or Hydralazine demonstrated that levels of circulating
methylated Rasal1 promoter DNA fragments were signiﬁcantly in-
creased in mice with kidney ﬁbrosis due to challenge with either UUO
or FA as compared to control mice receiving vehicle-buffer PBS
(Fig. 9A, B, compare to Fig. 1 and Supplementary Fig. 1). In mice with
ameliorated ﬁbrosis due to treatment with de-methylating agent 5′-
Azacytidine or Hydralazine, levels of circulating Rasal1 promoter DNA
fragments were signiﬁcantly reduced when compared to ﬁbrotic un-
treated mice (Fig. 9A, B), correlating with reduced ﬁbrosis (compare
to Fig. 1 and Supplementary Fig. 1). Circulating levels of methylated
Rasal1 promoter DNA fragments correlated with degree of intrarenal
Rasal1 promoter CpG island methylation (Fig. 9C, D). From this data
we concluded that circulatingRasal1 promoter DNA fragments correlate
with intrarenal Rasal1 promoter CpG island methylation, and possibly
with extent of ﬁbrosis in experimental renal ﬁbrosis as it does in cancer
patients. We also concluded that longitudinal analysis of circulating
methylated Rasal1 promoter DNA fragments reﬂected therapeutic efﬁ-
cacy of de-methylating agents 5′-Azacytidine and Hydralazine.
We next explored the possibility that circulatingmethylated RASAL1
promoter fragments could similarly reﬂect intrarenal RASAL1methyla-
tion (and possibly ﬁbrosis) in patients with CKD as they do in mice.
We analyzed kidney biopsy specimens and matching peripheral blood
samples from a small cohort of patients with varying degree of renal ﬁ-
brosis at time of biopsy (Supplementary Table D). Renal ﬁbrosis was in-
versely correlated with intrarenal RASAL1 mRNA expression levels
(Fig. 10A) and the degree of intrarenal RASAL1 promoter CpG island
methylation correlated with the degree of renal ﬁbrosis, irrespective
of the underlying disease (Fig. 10B), validating previous studies
(Tampe et al., 2014). Analysis of circulatingmethylated RASAL1 promot-
er DNA fragments demonstrated that levels of circulating methylated
RASAL1 promoter fragments reﬂect intrarenal RASAL1 promoter CpG is-
landmethylation (Fig. 10C). In this cohort, positive correlation betweens DNA hydroxylase Tet3. (A) As analyzed by qRT-PCR, Hydralazine treatment is associated
ere done in triplicate, data are presented as means ± s.e.m. *p b 0.05, n.s. no signiﬁcance,
epresentative analysis of cells which had been transfected with scrambled siRNA (left) or
nor Tet2 affected the efﬁcacy of Hydralazine to induce Rasal1 promoter de-methylation,
dralazine to normalize Rasal1methylation due to inefﬁcacy of Rasal1 hydroxymethylation
ffer PBS, 5′-Azacytidine, or Hydralazine, Rasal1 mRNA expression levels were analyzed by
alazine to restore Rasal1 mRNA expression. In contrast, Hydralazine no longer normalized
periments were done in triplicate, data are presented as means ± s.e.m. *p b 0.05, n.s. no
sistent with failure of Hydralazine to normalize Rasal1 promoter methylation and mRNA
brotic ﬁbroblast cultures (experiments were replicated four times, data are presented as
s vehicle-treated cultures).
30 B. Tampe et al. / EBioMedicine 2 (2015) 19–36circulating RASAL1 promoter fragment levels and degree of interstitial
ﬁbrosis at the time of biopsy was superior to that of estimated glomer-
ular ﬁltration rate (eGFR), serum creatinine, or blood urea nitrogen
(BUN) levels (Fig. 10D).
We next aimed to gain insights into the de-methylating activity of
Dihydralazine in patients with CKD. For this purpose we compared
levels of circulatingmethylated RASAL1 promoter DNA fragments in pa-fibrotic+5’-Azacytidine
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Fig. 6.Normalization of Rasal1methylation by Hydralazine involves DNA glycosylase Tdg.
(A) As analyzed by qRT-PCR, Hydralazine administration is associated with induction of
DNA glycosylases Tdg and Smug 1 (experiments were done in triplicate, data are present-
ed as means ± s.e.m. *p b 0.05, n.s. no signiﬁcance, values of pwere calculated respective
to vehicle-treated ﬁbrotic cultures). (B) Cells had been transfected with scrambled siRNA
(left) or with siRNAs targeting Tdg (middle) or Smug1 (right). Knockdown of Tdg resulted
in impaired Rasal1 promoter de-methylation uponHydralazine treatment whereas deple-
tion of Smug1 did not affect normalization of Rasal1 promoter methylation. (C) Whereas
knockdown of Smug1 did not affect normalization of Rasal1 mRNA expression upon Hy-
dralazine treatment, Hydralazine failed to restore Rasal1 expression levels when Tdg
was depleted (experiments were done in triplicate, data are presented as means ±
s.e.m. *p b 0.05, n.s. no signiﬁcance, values of pwere calculated respective to vehicle-treat-
ed ﬁbrotic cultures). (D) Consistent with insufﬁcient normalization of Rasal1 promoter
methylation and mRNA expression after Tdg depletion, Hydralazine no longer decreased
the proliferative activity of ﬁbrotic ﬁbroblast cultures (experiments were replicated four
times, data are presented as means ± s.e.m. *p b 0.05, n.s. no signiﬁcance, values of p
were calculated respective to two days vehicle-treated cultures).D
Ctientswith comparable stage of chronic kidney disease due tomalignant
arterial hypertension (HTN) with or without Dihydralazine treatment
(Supplementary Table E). Levels of circulating RASAL1 promoter DNA
fragments were signiﬁcantly decreased in patients on Dihydralazine
medication as compared to patients who did not receive Dihydralazine
(Fig. 10E). In two CKD patients who were newly put on Dihydralazine
medication due to therapy-resistant arterial HTN (Supplementary
Table F), we observed decreased levels of circulating RASAL1 promoter
DNA fragments within one week of Dihydralazine treatment
(Fig. 10F), providing evidence that lower levels of circulating RASAL1
promoter DNA fragments in the Dihydralazine group were a direct re-
ﬂection of Dihydralazine's de-methylating activity.
3.7. Evidence for Dose-dependency of Reno-protective Effect of Hydralazine
Comparison of our promising ﬁndings in mice with existing litera-
ture revealed that the Hydralazine dose which we used in our animal
studies, and which had been established as an optimum de-
methylating dose in previous cancer studies (5 mg/kg/day), does not
lower blood pressure and was below the anti-hypertensive dose com-
monly used inmice (50 mg/kg applied up to four times daily). To enable
better comparison of our studies with the bulk of existing literature, we
performed an additional set of experiments in which we challenged
mice with UUO (causing ﬁbrosis in the obstructed kidney without hy-
pertension), administered Hydralazine at doses of either 5 mg/kg/day
or 50 mg/kg/day and collected kidneys for analyses after three, seven,
and ten days of ureteral obstruction for tissue analysis. While degree
of ﬁbrosis and ﬁbroblast accumulation was signiﬁcantly improved in
mice that received low-dose Hydralazine at 5 mg/kg/day as compared
to mice that received vehicle buffer PBS, we did not observe signiﬁcant
protection from ﬁbrosis in mice that received high-dose Hydralazine at
50 mg/kg/day (Fig. 11A–D). Because Rasal1methylation and transcrip-
tional silencing were equally blunted in kidneys of mice which had re-
ceived either 5 mg/kg/day or 50 mg/kg/day Hydralazine (Fig. 11E, F),
we hypothesized that additional adverse effects, independent of CpG is-
land promoter de-methylation, might be induced in a dose-dependent
manner. In this regard, previous studies suggested that Hydralazine
could directly enhance intracellular levels of Hypoxia-inducible factor
1-α (Hif1α), a well-established enhancer of chronic progressive kidney
disease (Knowles et al., 2004). Therefore we analyzed Hif1α in our co-
horts of Hydralazine-treatedUUOmice by SDS-Page of total kidney pro-
tein lysates and subsequent immunoblotting and found levels of Hif1α
markedly increased in kidneys of mice that received high-dose Hydral-
azine at 50 mg/kg/day, but not in kidneys of mice which had received
Hydralazine at 5 mg/kg/day (Fig. 11G).
We next aimed to gain possible insights into the reno-protective
efﬁcacy of low-dose Hydralazine in patients. For this purpose, we
performed retrospective analysis on patients compared to patients
with impaired kidney function (CKD3) due to malignant hyperten-
sion and we compared patients who were maintained on low-dose
Dihydralazine (12.5 to 25 mg/day) over more than 12 months to
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Fig. 7. Impact of 5′-Azacytidine andHydralazine onmRNA expression levels of genes involved in CpGmethylation and de-methylation in vivo. (A–D)Micewere challengedwith unilateral ure-
teral obstruction (UUO) and treatedwith either vehicle buffer PBS, 5′-Azacytidine, orHydralazine (10 mg/kg/day or 5 mg/kg/day, respectively) and sacriﬁced ten days after ureteral obstruction
whenkidneys haddeveloped severe tubulointerstitialﬁbrosis.mRNAexpression levels of Dnmt1 andDnmt3awerenormalized after treatmentwith 5′-Azacytidine andHydralazine. Among Tet
hydroxylases, Hydralazine induced expression of Tet3, but not of Tet1 or Tet2, whereas 5′-Azacytidine did not increase expression of either Tet gene. Hydralazine treatment had no effect on
expression levels of cytosine deaminases Aicda, Apobec1, or Apobec3, whereas DNA glycosylases Tdg and Smug 1 were induced after Hydralazine administration in UUOmice, 5′-Azacytidine
didnot impactmRNAexpression levels (experimentsweredone in triplicate, data are presented asmeans± s.e.m. *pb 0.05, n.s. no signiﬁcance, values ofpwere calculated respective to vehicle-
treated UUO mice).
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32 B. Tampe et al. / EBioMedicine 2 (2015) 19–36patients on standard anti-hypertensive Dihydralazine regimen (100
to 200 mg/day) and with a cohort of patients without anti-
hypertensive Dihydralazine treatment (Supplementary Table G).
While serum creatinine levels increased over 12 months at typical
rates, Dihydralazine given at standard regimen had no effect, where-
as increase of serum creatinine levels was signiﬁcantly blunted in
those patients in which Dihydralazine had been maintained at low
dosages independent of impact on blood pressure mirroring our ob-
servations in mice (Fig. 11H and Supplementary Fig. 11A, B).sh
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Fig. 9. Circulating Rasal1 promoter DNA fragments correlate with intrarenal Rasal1 pro-
moter methylation and kidney ﬁbrosis in mouse models of experimental ﬁbrogenesis.
(A–D) Experimental renal ﬁbrogenesis is associated with increased intrarenal Rasal1
methylation and circulatingRasal1promoterDNA fragments.Mice challengedwith unilat-
eral ureteral obstruction (UUO) or folic acid-induced nephropathy (FA)were treatedwith
either vehicle buffer PBS, 5′-Azacytidine, or Hydralazine (10 mg/kg/day or 5 mg/kg/day,
respectively) andmethylatedDNAwas isolated fromkidney and correlated blood samples
usingmethylated DNA immunoprecipitation (MeDIP). Compared to healthy control mice,
kidney ﬁbrosis in both mouse models used was associated with increased intrarenal
Rasal1methylation and circulating methylated Rasal1 promoter DNA fragments, whereas
treatment with anti-ﬁbrotic and de-methylating 5′-Azacytidine or Hydralazine normal-
ized intrarenal Rasal1 methylation associated with decreased circulating methylated
Rasal1 DNA fragments. Circulating methylated Rasal1 promoter DNA fragments reﬂected
intrarenal Rasal1methylation in mice challenged with experimental kidney ﬁbrosis (ex-
periments were done in triplicate, data are presented as scatter dot blots with lines at
means. *p b 0.05, values of p were calculated respective to vehicle-treated ﬁbrotic mice,
r2 and p value are presented in the correlation analysis).4. Discussion
This study adds further evidence for a contribution of aberrant pro-
moter CpG island methylation to the progression of renal ﬁbrogenesis
and its potential as a biomarker and therapeutic target. While there
are likely additional genes affected byCpG island promotermethylation,
this study provides mechanistic evidence for the ﬁrst time that aberrant
transcriptional silencing of Rasal1 causally contributes to progression of
renal ﬁbrogenesis and that Rasal1methylation is not just part of an un-
speciﬁc methylation signature in renal ﬁbrosis. In this regard, normali-
zation of aberrant promoter methylation through administration of 5′-
Azacytidine or Hydralazine was associated with attenuated ﬁbroblast
activation and ﬁbrogenesis in experimental ﬁbrosis. Due to DNA incor-
poration, 5′-Azacytidine and its derivate 5′-Aza-2′-Deoxycytidine have
considerable cytotoxicity, in addition to their unspeciﬁc de-
methylating activity. Hydralazine is not incorporated into DNA and re-
cruits crucial steps in dynamic DNA de-methylation involving Tet3-
mediated formation of 5-hydroxymethyl-cytosine (5hmC), 5-formyl-
cytosine (5fC), and 5-carboxyl-cytosine (5caC) with subsequent Tdg-
mediated excision and replacement with naked cytosine (Fig. 12A–C).
Due to the CXXC motif target selectivity of Tet proteins, which directs
Tet3 directly to the CpG islands within the RASAL1 promoter, one can
speculate that the de-methylating activity ismore speciﬁc for aberrantly
methylated genes as compared to 5′-Azacytidine, possibly accounting to
its benign toxicity (Bechtel et al., 2010; Xu et al., 2012). Due to the
prominent functional contribution of RASAL1 promoter CpG island
methylation to progression of chronic kidney disease, tools to speciﬁcal-
ly de-methylate RASAL1 should be developed and explored in the future.
Our study adds further evidence for the utility of RASAL1methyla-
tion as a biomarker of renal ﬁbrosis, which is not surprising as severaltranscriptional proﬁling studies revealed that RASAL1 expression is con-
sistently decreased in kidney biopsies frompatientswith chronic kidney
disease (Tampe et al., 2014). Importantly, we demonstrate for the ﬁrst
time that circulating methylated RASAL1 CpG island promoter frag-
ments correlate with degree of intrarenal RASAL1 methylation and
degree of ﬁbrosis, similar to increased levels of methylated CpG frag-
ments which can be detected in cancer patients. While the mechanism
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Fig. 10. Circulating RASAL1 promoter DNA fragments correlate with intrarenal RASAL1 promoter methylation and degree of ﬁbrosis in CKD patients irrespective of the underlying disease.
(A) Kidney ﬁbrosis negatively correlatedwith endogenous RASAL1mRNA expression levels (experiments were done in triplicate, r2 and p value are presented in the correlation analysis).
(B, C) Extent of interstitial ﬁbrosis is positively correlated with intrarenal RASAL1 promoter methylation associated with increased levels of circulating RASAL1 promoter DNA fragments
(experiments were done in triplicate, r2 and p value are presented in the correlation analysis). (D) Compared to conventional parameters of renal function estimated glomerular ﬁltration
rate (eGFR), serum creatinine, or blood urea nitrogen (BUN), circulating methylated RASAL1 promoter DNA fragments correlated best with extent of tubulointerstitial ﬁbrosis of corre-
sponding patients (r2 and p values are presented in the corresponding correlation analysis). (E) In hypertensive patients with CKD (right panels in pink), Dihydralazine medication
was associated with normalization of circulating methylated RASAL1 promoter DNA fragments (n = 4 in each group, experiments were done in triplicate, data are presented as scatter
dot blots with lines at means. *p b 0.05, value of p was calculated respective to patients with HTN and CKD without Dihydralazine medication). (F) Increased circulating methylated
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as scatter dot blots with connection lines of means. *p b 0.05, value of p was calculated respective to analysis before initiation of Dihydralazine medication).
33B. Tampe et al. / EBioMedicine 2 (2015) 19–36of howmethylated promoter CpG island fragments are released into the
circulation is not clear, we suspect that they are unspeciﬁcally liberated
from injured cells, similar to what is observed in solid tumors. Because
levels of methylated Rasal1 CpG island promoter fragments decreased
in mice which were treated with de-methylating and anti-ﬁbrotic
agent 5′-Azacytidine or Hydralazine, we speculate that circulating
methylated DNA fragment levels dynamically reﬂect RASAL1 CpG island
promoter methylation within the kidney and may have utility to moni-
tor effectiveness of de-methylating and anti-ﬁbrotic therapies. As such
decrease in circulating methylated Rasal1 CpG island promoter frag-
ments in mice correlated with blunted kidney ﬁbrosis upon de-
methylating therapy, it is attractive to speculate that decreased levels
of methylated RASAL1 DNA fragments and blood pressure-
independent attenuation of CKD progression which were observed inpatients which had received low-dose Dihydralazine are also reﬂective
of its potential reno-protection.
Our ﬁnding that Hydralazine inhibits renal ﬁbrosis due to the induc-
tion of active DNA de-methylation begs the question of why such a ben-
eﬁcial effect has gone unnoticed for a drug that has been used for more
than 50 years. In this regard, existing data on a potential reno-
protective effect of Hydralazine are inconclusive. While Hydralazine
was long part of the standard-triple anti-hypertensive regimen (Hydro-
chlorothiazide, Propranolol, and Hydralazine), it was largely replaced
when cardio-protective efﬁcacy of ACEIs and ARBs was proven in large
clinical trials (Heagerty et al., 1982). Hydralazine/Dihydralazine today
is mainly used as third-line drug in patients with therapy-resistant hy-
pertension (Leonetti et al., 1990). One reason the reno-protective effects
of Hydralazine/Dihydralazine have never been documented may well
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cytosine.
35B. Tampe et al. / EBioMedicine 2 (2015) 19–36be, that to our knowledge, such clinical trials to assess reno-protective
effects have never been conducted. The rapid improvement of renal ex-
cretory function upon Hydralazine/Dihydralazine medication was ob-
served soon after its introduction and attributed to unspeciﬁed
vascular and hemodynamic effects at that time (Hollander et al., 1956;
Pierpont et al., 1980). Because Hydralazine/Dihydralazine treatment is
typically initiated at low doses of 12.5 mg (to avoid reﬂex tachycardia)
before doses are increased to typical anti-hypertensive regimen of
100 mg, it is based on our clinical analysis tempting to speculate thatFig. 11. Comparison of low-dose and high-dose Hydralazine administration in experimental kidn
stained (MTS), αSMA or Fsp1 immunolabeled kidney sections from mice receiving either vehicl
shows ﬁbrotic kidney sections from mice challenged with UUO at indicated time points after ure
with low-dose Hydralazine attenuated renal ﬁbrogenesis and ﬁbroblast accumulation. In contras
50 μm). (B–D) The time course summarizes average values at the indicated time points of each
were calculated respective to vehicle-treated UUOmice). (E, F) Rasal1 promotermethylationwas a
with either vehicle buffer PBS, 5 mg/kg/day (low-dose), or 50 mg/kg/day Hydralazine (high-dose
UUOmice, both concentrations of Hydralazine were capable to normalize Rasal1 promoter methy
are presented as means ± s.e.m. *p b 0.05, values of pwere calculated respective to vehicle-treate
immunoblotting, we found levels of Hif1αmarkedly increased in kidneys of mice that received hig
azine at 5 mg/kg/day (n = 3 in each group). (H) Compared to hypertensive patients without Dih
tenuation of CKD progression indicated by blunted rise of serum creatinine from baseline over
(n = 5, data are presented as scatter dot blots with lines at means. *p b 0.05, n.s. no signiﬁcance,those dynamics of excretory kidney function are a direct reﬂection of
Hydralazine/Dihydralazine used. Few small clinical studies report
delay of progression of CKD upon medication with Hydralazine/
Dihydralazine (Mogensen, 1976; Parving et al., 1993). Studieswhich an-
alyzed reno-protective efﬁcacy of Hydralazine in rodent models of
chronic kidney disease revealed conﬂicting results (Soto et al., 2004;
Velasquez et al., 1997; Djukanovic et al., 1994). It is tempting to specu-
late that Hydralazine dosagemight play a role in conﬂicting studies. It is
well established that Hydralazine exerts its de-methylating activity atey ﬁbrosis and CKD patients. (A) Representative photomicrographs of Masson's trichrome-
e buffer PBS, low-dose (5 mg/kg/day) or high-dose Hydralazine (50 mg/kg/day). The panel
teral obstruction. As compared to control mice receiving vehicle buffer PBS, only treatment
t, high-dose Hydralazine failed to attenuate kidney ﬁbrosis in this mouse model (scale bars:
group (n = 6 in each group, data are presented as means ± s.e.m. *p b 0.05, values of p
nalyzed byMeDIP inmice challengedwith unilateral ureteral obstruction (UUO) and treated
), Rasal1 mRNA expression levels were analyzed by qRT-PCR. As compared to vehicle-treated
lation andmRNA expression (n= 6 in each group, experiments were done in triplicate, data
d UUOmice). (G) As determined by SDS-Page of total kidney protein lysates and subsequent
h-dose Hydralazine at 50 mg/kg/day, but not in kidneys of mice which had received Hydral-
ydralazine medication (n = 4), low-dose Dihydralazine medication was associated with at-
time (n = 3). In contrast, high doses of Dihydralazine failed to attenuate CKD progression
values of pwere calculated respective to patients without Dihydralazine medication).
36 B. Tampe et al. / EBioMedicine 2 (2015) 19–36lower doses than its anti-hypertensive effect and that de-methylating
efﬁcacy does not increase at higher doses, as our studies showed
(Zambrano et al., 2005). Our observation that high doses of Hydralazine
induce adverse side effects such as Hif1α accumulation offers a possible
explanation for conﬂicting studies (which were mostly performed at
doses of 50 mg/kg/day and higher). Regarding the interpretation of
the effect of Hydralazine/Dihydralazine therapy in existing patient co-
horts, it has to be considered that doses used in patients are generally
ten-fold lower than doses used in mice (due to resistance of mice to re-
spond to anti-hypertensive action of Hydralazine).
Nevertheless, due to the high prevalence of hypertension in patients
with CKD, low-dose Hydralazine/Dihydralazine as an add-on to current
treatment regimens appears attractive aswell as safe andmight deserve
reconsideration andprospective clinical testing. In combinationwith as-
sessment of levels of methylated RASAL1 DNA fragments in the blood
without further need for biopsy, the possibility exists that this could
be conducted in a biomarker therapy-stratiﬁed and biomarker moni-
tored fashion.
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